Clinical Research and Trials

Clinical research studies are vital to the process of discovering the safest and most effective cancer therapies for patients. The C.R. Wood Cancer Center currently has approximately 40 national clinical studies available for treatment, quality of life and prevention of different cancers. Glens Falls Hospital has partnered with the University of Vermont for shared opportunities in their clinical studies, and the center also participates in clinical studies directly through pharmaceutical companies. The physicians and staff of the C.R. Wood Cancer Center work closely with these well respected organizations, along with the National Cancer Institute, to provide opportunities for local patients to take part in national clinical research studies, without having to travel away from home. These studies provide the opportunity for patients to conveniently receive some of the most cutting edge therapies available, while also allowing them to directly contribute to the ongoing progress being made in the field of oncology. Treatment studies may consist of chemotherapy, immunotherapy, radiation therapy, hormonal therapy or combination therapy. Learn more about clinical trials by visiting clinicaltrials.gov

For more information on clinical studies, contact Beth Ann Brundage, RN, OCN, at 518-926-6644 or Nannette Oberhelman, at 518-926-6701.

Clinical Trials

ANOREXIA

CTSU A222004
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

BLADDER

CTSU    A032001  

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer

CTSU S1937

A Phase III Randomized Trial of Eribulin with or without Gemcitabine vs Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

BRAIN

CTSU    A071801  
Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS for Resected Metastatic Brain Disease

BREAST

CTSU A011801      
he CompassHER2 trials (COMprehensive use of Pathologic Response Assessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib

CTSU    EA1181        
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer)

CTSU NRG-BR007

A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer. (Also under Registries)

COLON/RECTAL

A021703
Randomized Double-Blind Phase III Trial of Vit. D3 Supplementation in Patients with Previously Untreated Met. Colorectal Ca (SOLARIS)

GI008

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

LEUKEMIA

CTSU A041702
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (Temporarily Suspended)

CTSU  S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab vs. DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study

LUNG

SCLC Limited

LU005  
Limited Stage Small Cell Lung Cancer: A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab

S1827
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

NSCLC Limited

CTSU A151216  NSCLC
Genetic Testing For Patients with Resectable or Resected Lung Cancer (ALCHEMIST)

CTSU E4512 
A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. (ALCHEMIST)

CTSU A081801
Integration of immune-therapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO Temporarily Suspended to Accrual

CTSU EA5181  
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

NSCLC Advanced

CTSU A171901
Older Non-Small Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)

CTSU  LUNGMAP
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

CTSU EA5182
Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer

LYMPHOMA

CTSU S1826    
Nivolumab (Opdivo) + AVD or Brentuximab Vedotin (Adetris) + AVD in Patients (Age >/= 12 yoa) with Newly Diagnosed Advanced Stage Classical Hodgkin’s Lymphoma

MDS

NHLBI-MDS 
The National Myelodysplastic Syndromes (MDS) Study: Recruiting Patients With Low Blood Counts Undergoing A Bone Marrow Assessment for Evaluation of MDS

MULTIPLE MYELOMA

CTSU EAA173   DETER-SMM
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

HEAD & NECK

NRG-HN009
Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell

PROSTATE

A031902 (CASPAR)
A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-resistant Prostate Cancer

S1802  
Phase III Randomized Trial of Standard Systemic Therapy (SST) vs. Standard Systemic Therapy Plus Definitive Treatment (Surgery or RT) of the Primary Tumor in Met. Prostate Ca 

RENAL

A031704
Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]

REGISTRIES

P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been  recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.

 

NOTE:  Other studies are available to us through the University of VT; we open them as Research Nurse identifies an eligible patient.

C.R. Wood Cancer Center
Research Office

Pruyn Pavilion at Glens Falls Hospital
2nd Floor
100 Park Street
Glens Falls, NY 12801

Phone: 518-926-6701
Fax: 518-926-1954

Clinical Trial Key:

A = Alliance (CALGB, ECOG, SWOG)

NRG = NSABP, RTOG, GOG

CTSU= NCI Cancer Trials Support Unit

P = Pharmacy

Updated 6/2022